SCHEMBL15033833

SCHEMBL15033833

c1ccc(CCc2nc(Nc3ccccc3)ncc2-c2ccco2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 6/20 0.47
MEN1 O00255 5/20 0.47
CYP3A4 P08684 5/20 0.47
KMT2A Q03164 5/20 0.47
HIF1A Q16665 4/20 0.47
CASP7 P55210 4/20 0.47
CYP1A2 P05177 4/20 0.47
CYP2C19 P33261 3/20 0.47
CYP2C9 P11712 3/20 0.47
HSD17B10 Q99714 3/20 0.47
IGF1R P08069 2/20 0.44
ADORA2B P29275 4/20 0.43
ADORA1 P30542 4/20 0.43
CLK4 Q9HAZ1 2/20 0.43
ADORA3 P0DMS8 2/20 0.43
MAP4K4 O95819 1/20 0.43
FLT3 P36888 1/20 0.43
CSNK1D P48730 1/20 0.43
AURKB Q96GD4 1/20 0.43
MAP3K20 Q9NYL2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL670753 0.75 CASP1 (0.57) CASP1MEN1CYP3A4KMT2AHIF1A
SCHEMBL669492 0.75 AURKA (0.59) CASP1MEN1CYP3A4KMT2AHIF1A
SCHEMBL669197 0.75 IGF1R (0.59) CASP1MEN1CYP3A4KMT2AHIF1A
SCHEMBL669722 0.74 TYRO3 (0.58) CASP1MEN1CYP3A4KMT2AHIF1A
SCHEMBL15033852 0.73 CASP1 (0.47) CASP1MEN1CYP3A4KMT2AHIF1A
SCHEMBL669825 0.72 ULK1 (0.61) CASP1MEN1CYP3A4KMT2AHIF1A
SCHEMBL12190152 0.70 CYP1A2 (0.50) CASP1MEN1CYP3A4KMT2AHIF1A
SCHEMBL15033834 0.70 GSK3B (0.64) CASP1MEN1CYP3A4KMT2AHIF1A
SCHEMBL15023605 0.68 FLT4 (0.49) CASP1MEN1CYP3A4KMT2AHIF1A
SCHEMBL27589833 0.68 ADORA2B (0.53) IGF1RADORA2BADORA1CLK4ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2606034-B1 PYRIMIDINE DERIVATIVE AS FAK INHIBITORS MERCK PATENT GMBH (DE) 2016-03-09 EP disclosed
US-8906916-B2 Pyrimidine derivatives as FAK inhibitors MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
US-8906916-B2 Pyrimidine derivatives as FAK inhibitors MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
US-20130158005-A1 PYRIMIDINE DERIVATIVES AS FAK INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-06-20 US disclosed
US-20130158005-A1 PYRIMIDINE DERIVATIVES AS FAK INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158005-A1 PYRIMIDINE DERIVATIVES AS FAK INHIBITORS CDK2, PTK2, CDKN1A CASP1 1959/4885MEN1 2958/4885CYP3A4 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.